-
Abstract: Chronic rhinosinusitis (CRS) is an inflammatory disease of the nasal airways and paranasal sinuses.The condition is defined by more than 12 weeks of nasal obstruction, nasal discharge, facial pain/pressure, and reduced/lost smell.CRS is commonly further classified into 2 subsets based on its clinical phenotype:those with polyps (CRSwNP) and those without (CRSsNP).The incidence of CRS increases year by year.Due to its persistent, intractable and easy to relapse, CRS seriously affects patient's daily work and life.In addition, CRS also increases the patient's financial burden.However, the etiology and pathogenesis of CRS is complex, which limited the clinical treatment in CRS.This review summarizes the latest advances in inflammatory pathways and biologics therapies of CRS based on the latest research results.
-
Key words:
- sinusitis /
- Type 2 inflammation /
- biologics /
- immune specific targeting
-
-
[1] MACRI G F, GRECO A, MARINELLI C, et al.Evidence and role of autoantibodies in chronic rhinosinusitis with nasal polyps[J].Int J Immunopathol Pharmacol, 2014, 27:155-161.
[2] ORLANDI R R, KINGDOM T T, HWANG P H, et al.International Consensus Statement on Allergy and Rhinology:Rhinosinusitis[J].Int Forum Allergy Rhinol, 2016, 6 (Suppl 1):S22-209.
[3] HIRSCH A G, STEWART W F, SUNDARESAN AS, et al.Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample[J].Allergy, 2017, 72:274-281.
[4] TOMASSEN P, VANDEPLAS G, VAN ZELE T, et al.Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers[J].J Allergy Clin Immunol, 2016, 137:1449-1456.e4.
[5] WANG X, ZHANG N, BO M, et al.Diversity of THcytokine profiles in patients with chronic rhinosinusitis:A multicenter study in Europe, Asia, and Oceania[J].J Allergy Clin Immunol, 2016, 138:1344-1353.
[6] 王晨霞, 袁芳.复发性鼻息肉的治疗新进展[J].临床耳鼻咽喉头颈外科杂志, 2016, 30 (19):1581-1584.
[7] LAM K, KERN RC, LUONG A.Is there a future for biologics in the management of chronic rhinosinusitis[J]?Int Forum Allergy Rhinol, 2016, 6:935-942.
[8] LIDDER A K, DETWILLER K Y, PRICE C P, et al.Evaluating metrics of responsiveness using patient-reported outcome measures in chronic rhinosinusitis[J].Int Forum Allergy Rhinol, 2017, 7:128-134.
[9] MIN J Y, OCAMPO C J, STEVENS W W, et al.Proton pump inhibitors decrease eotaxin-3/CCL26 expression in patients with chronicrhinosinusitis with nasal polyps:Possible role of the nongastric H, K-ATPase[J].J Allergy Clin Immunol, 2017, 139:130-141.
[10] SCHLEIMER R P.Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis[J].Annu Rev Pathol, 2017, 12:331-357.
[11] ARTIS D, SPITS H.The biology of innate lymphoid cells[J].Nature, 2015, 517:293-301.
[12] SALUJA R, KHAN M, CHURCH M K, et al.The role of IL-33and mast cells in allergy and inflammation[J].Clin Transl Allergy, 2015, 5:33.
[13] MAHDAVINIA M, CARTER R G, OCAMPO C J, et al.Basophils are elevated in nasal polyps of patients with chronic rhinosinusitis without aspirinsensitivity[J].J Allergy Clin Immunol, 2014, 133:1759-1763.
[14] KATO A.Immunopathology of chronic rhinosinusitis[J].Allergol Int, 2015, 64:121-130.
[15] STEVENS W W, OCAMPO C J, BERDNIKOVS S, et al.Cytokines in chronic rhinosinu-sitis.Role in eosinophilia and aspirin-exacerbated respiratory disease[J].Am J Respir Crit Care Med, 2015, 192:682-694.
[16] GEVAERT P, LANG-LOIDOLT D, LACKNER A, et al.Nasal IL-5levels determine the response to antiIL-5treatment in patients with nasal polyps[J].J Allergy Clin Immunol, 2006, 118:1133-1141.
[17] GEVAERT P, VAN BRUAENE N, CATTAERTT, et al.Mepolizumab, a humanized anti-IL-5mAb, as a treatment option for severe nasal polyposis[J].JAllergy Clin Immunol, 2011, 128:989-995.
[18] BLEECKER E R, FITZGERALD J M, CHANEZ P, et al.Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corti-costeroids and long-acting beta2-agonists (SIROCCO):a randomised, multicen-tre, placebocontrolled phase 3trial[J].Lancet, 2016, 388:2115-2127.
[19] PINTO J M, MEHTA N, DITINEO M, et al.A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis[J].Rhinology, 2010, 48:318-324.
[20] GEVAERT P, CALUS L, VAN ZELE T, et al.Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma[J].J Allergy Clin Immunol, 2013, 131:110-116.e1.
[21] CHANDRA R K, CLAVENNA M, SAMUELSONM, et al.Impact of omalizumab therapy on medication requirements for chronic rhinosinusitis[J].Int Forum Allergy Rhinol, 2016, 6:472-477.
[22] BACHERT C, MANNENT L, NACLERIO R M, et al.Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis:A Randomized Clinical Trial[J].JAMA, 2016, 315:469-479.
[23] SCHLEIMER R P, SCHNAAR R L, BOCHNER B S.Regulation of airway inflammation by Siglec-8and Siglec-9sialoglycan ligand expression[J].Curr Opin Allergy Clin Immunol, 2016, 16:24-30.
[24] KOUZAKI H, MATSUMOTO K, KATO T, et al.Epithelial Cell-Derived Cytokines Contribute to the Pathophysiology of Eosinophilic Chronic Rhinosinusitis[J].J Interferon Cytokine Res, 2016, 36:169-179.
[25] BOITA M, GARZARO M, RAIMONDO L, et al.Eosinophilic inflammation of chronic rhinosinusitis with nasal polyps is related to OX40 ligandexpression[J].Innate Immun, 2015, 21:167-174.
[26] SEL S, WEGMANN M, DICKE T, et al.Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme[J].J Allergy Clin Immunol, 2008, 121:910-916.
[27] KRUG N, HOHLFELD J M, KIRSTEN A M, et al.Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme[J].N Engl J Med, 2015, 372:1987-1995.
[28] DWORETZKY S I, HEBRANK G T, ARCHIBALDD G, et al.The targeted eosinophillowering effects of dexpramipexole in clinical studies[J].Blood Cells Mol Dis, 2017, 63:62-65.
-
计量
- 文章访问数: 82
- PDF下载数: 38
- 施引文献: 0
下载: